What maintenance means on the label
Both weight-management labels use the word in two ways. First, as an indication: Wegovy and Zepbound are approved, alongside a reduced-calorie diet and more physical activity, to reduce excess body weight and to maintain that reduction long term. Maintenance is part of what these medications are approved for, not an afterthought.
Second, as a dosing phase. Treatment starts low and steps up at set intervals, mainly to reduce gastrointestinal side effects, until it reaches a maintenance dosage. Both labels list more than one maintenance dosage and tell prescribers to weigh treatment response and tolerability when choosing between them. So even on the label, maintenance is not a single fixed point that everyone lands on.
What the labels do not describe is a planned step-down after goal weight, or dosing less often than weekly. Those are the questions most people are really asking, and the answers come from research rather than the label.
Is maintenance the same as being at goal weight?
No. On the label, maintenance describes the dose you continue on after escalation, and in the trials people kept losing weight for months after reaching it. Being at a weight you want to keep is a separate milestone, and it is often the point where the conversation about what comes next begins.
What happened when trial participants stopped
Four trials answer this directly. Three are randomized withdrawal trials: everyone takes the medication for a period, then half are switched to placebo without knowing it. The fourth followed people for a year after all treatment ended. Dose amounts are left out below. What matters is the comparison between continuing and stopping.
| Trial | Design | What happened |
|---|---|---|
| STEP 4 (semaglutide), JAMA 2021 | 20 weeks on semaglutide (average loss 10.6%), then 48 weeks randomized to continue or switch to placebo | Those who continued lost a further 7.9%. Those switched to placebo regained 6.9%. |
| STEP 1 extension (semaglutide), Diabetes Obes Metab 2022 | 68 weeks of semaglutide, then medication and the lifestyle program both stopped; 327 people followed for another year | Average loss of 17.3% at week 68. By week 120, 11.6 percentage points had come back, leaving a net loss of 5.6%. Most cardiometabolic improvements drifted back toward baseline. |
| SURMOUNT-4 (tirzepatide), JAMA 2024 | 36 weeks on tirzepatide (average loss 20.9%), then 52 weeks randomized to continue or switch to placebo | Continuing: a further 5.5% loss. Placebo: 14.0% regained. 89.5% of those continuing kept at least 80% of their loss, against 16.6% on placebo. |
| SURMOUNT-MAINTAIN (tirzepatide), Lancet 2026 | 60 weeks at the highest dose each person tolerated, then 52 weeks randomized to continue, step down to a lower dose, or switch to placebo | Total loss from the start: 21.9% continuing, 16.6% on the lower dose, 9.9% on placebo. Rescue treatment for regaining at least half the loss was needed by 8%, 25% and 67% respectively. |
How much weight comes back after stopping a GLP-1?
On average, a lot of it. In the STEP 1 extension, people regained about two-thirds of their prior weight loss within a year of stopping. In SURMOUNT-4, the placebo group regained 14% of their body weight over the following year. On average, it did not return people all the way to where they started.
Does everyone regain weight?
No. These are averages, and averages hide wide spreads in both directions. Some participants kept most of their loss after stopping and some on continued treatment regained. What the trials establish is the direction of the effect for most people, not a prediction for you.
One detail is easy to miss. In the STEP 1 extension, the structured lifestyle program ended at the same time as the medication. It measures stopping everything at once, which is not the same as stopping the medication while deliberately keeping the habits.
Why does weight come back?
A 2026 review in Diabetes, Obesity and Metabolism describes regain as a biological response to weight loss, including a return of appetite signaling and changes in energy expenditure, rather than a failure of willpower. That is the reasoning behind treating obesity as a chronic condition, and why the trial authors concluded that ongoing treatment is usually needed to maintain the benefits.
From the makers of this guide
How Pep AI supports the maintenance phase
Maintenance is mostly a monitoring problem. Regain rarely announces itself, but it shows up early in the numbers if you are looking. Pep AI keeps the numbers that matter in one place.
- 01
Weight trend and progress photos
Log weigh-ins and photos to see the trend rather than the daily noise, so a slow drift is visible months before it becomes a surprise.
- 02
Protein, fiber and water against goals
Log food by photo, barcode, restaurant menu scan, search, recents or quick-add macros, and see protein, fiber and water against the targets you set.
- 03
Workout logging
Record resistance sessions so strength training, the habit most tied to keeping lean mass, stays a routine rather than an intention.
- 04
Dose log and reminders
Whatever plan you and your prescriber settle on, reminders follow your schedule and every dose is logged with its date, so the plan and what happened match.
Lower doses or longer gaps: what is known
Many people want to know whether they can hold their weight on less medication. It is a reasonable question, and the research is only starting to answer it. There are three separate ideas here, and the strength of the evidence differs sharply between them.
Can a lower maintenance dose keep the weight off?
SURMOUNT-MAINTAIN is the first randomized trial built to test this for tirzepatide. Stepping down to a lower dose held more weight off than placebo, but less than staying on the higher dose, and about a quarter of the lower-dose group regained enough to need rescue treatment. The authors called the lower dose a possible alternative to stopping and noted that individual response may vary.
That is useful evidence for a prescriber weighing options with you. It is not a protocol, and it covers one drug in one trial.
Is spacing doses further apart than weekly an option?
Every approved label here describes weekly dosing only, so injecting less often is off-label. The published evidence so far is thin: a 2026 retrospective case series of 30 adults, with no comparison group, reported that weight held steady after they moved to less frequent dosing. A study like that can raise a question but cannot tell you whether the approach works or is safe. A 2026 review noted that validated tapering strategies do not yet exist.
Spacing doses changes how much medication is in your body between injections, and it interacts with the missed-dose and restart rules on your label. It is a decision to make with your prescriber, never on your own.
What about stopping completely?
The withdrawal trials above are the evidence, and on average they point to substantial regain. That does not make stopping wrong. Cost, side effects, pregnancy plans and personal preference are all legitimate reasons. It does mean stopping works best as a planned transition with your prescriber, with a clear idea of what you will monitor and what would prompt a rethink.
Habits linked to keeping weight off
Long before GLP-1s, the National Weight Control Registry studied people who had lost weight and kept it off for years. A review of that registry found that people who kept weight off reported high levels of physical activity, regular self-weighing, and a consistent eating pattern across weekdays and weekends. It also found that maintenance appeared to get easier with time.
A 2025 joint advisory from four obesity and nutrition societies adds the GLP-1-specific layer: resistance training and an appropriate diet to preserve muscle and bone, attention to nutrient gaps when intake is low, and support from dietitians or digital tools. It also lists nutrition for maintenance after stopping as an area that still needs research.
- Protein: keep it a priority at every meal. It supports lean mass while intake is low, and it is one of the few levers entirely in your control.
- Resistance training: it signals your body to keep lean tissue, which is thought to help protect the energy expenditure that maintenance relies on.
- Weighing yourself regularly: regular weighing turns slow regain into an early signal instead of a late surprise.
- A regain threshold agreed in advance: decide with your prescriber how much regain would prompt a review, so the conversation happens on data rather than on worry.
- Consistency: steady eating and activity patterns across the week, not strict weekdays followed by loose weekends.
Questions to take to your prescriber
The maintenance conversation is easier when you bring specifics. None of these questions asks for a dose. They ask for a plan.
- Given how I have responded and what side effects I have had, which maintenance options on my label make sense for me?
- If we change anything, what should I watch for, and when do we review?
- How much regain should prompt a call, and what would we do then?
- If I stop, how should I restart if I need to, given the gastrointestinal side effects of re-escalation?
- Which labs or measurements (weight, waist, blood pressure, glucose) should we keep tracking?
Key takeaways
- The weight-management labels include keeping weight off long term, and list more than one maintenance dosage chosen by response and tolerability.
- In withdrawal trials, most people who stopped regained much of their loss within a year. In the STEP 1 extension it was about two-thirds.
- A lower dose held more weight than placebo but less than continuing in the one randomized trial so far. Spacing doses out beyond weekly is off-label and largely unstudied.
- Protein, resistance training, regular weighing and a consistent routine are the habits most linked to keeping weight off.
- Any change to dose or schedule is a prescriber decision. Bring a plan for monitoring, not just a question about the dose.
Watch the trend, not the scale's mood.
Pep AI puts your weight trend, protein, workouts and dose history in one place, so the maintenance conversation with your prescriber starts from real data. Download Pep AI on iPhone or Android.
Frequently asked questions
Keep reading
Sources
- Wegovy (semaglutide) injection and tablets prescribing information, Novo Nordisk / FDA
- Zepbound (tirzepatide) prescribing information, Eli Lilly / FDA
- Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA 2021
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab 2022
- Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA 2024
- Horn DB et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity (SURMOUNT-MAINTAIN). Lancet 2026
- Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr 2005
- Mozaffarian D et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory. Am J Clin Nutr 2025
This guide is general information about GLP-1 medications, based on prescribing information and published research. It is not medical advice and does not replace your prescriber or pharmacist. Do not change your dose or schedule without your prescriber. If a symptom is severe, getting worse, or worrying you, contact your healthcare provider. In an emergency, call 911.
Published by the Pep AI team · Updated September 2026